Don’t miss the latest developments in business and finance.

Lupin's Mandideep Unit II facility receives EIR from USFDA

Image
Press Trust of India New Delhi
Last Updated : Apr 15 2020 | 10:32 AM IST

Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh.

The inspection at the facility was carried out by the US Food and Drug Administration between November 26, 2018, and December 4, 2018.

In a filing to BSE, the company said Lupin has received the EIR after closure of the USFDA inspection of its Mandideep Unit II facility, classifying the inspection as "Voluntary Action Indicated."

Also Read

First Published: Apr 15 2020 | 10:32 AM IST

Next Story